Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin
Phase 2
Completed
- Conditions
- Photo-damage
- Interventions
- Drug: PEP005 (ingenol mebutate) Gel
- Registration Number
- NCT01214577
- Lead Sponsor
- Peplin
- Brief Summary
This study is primarily designed to evaluate the safety and tolerability of PEP005 Gel, 0.015% when administered for up to three consecutive days to photo-damaged skin on the face. The secondary endpoint is to determine the efficacy of PEP005 Gel, 0.015% when administered for up to three consecutive days in patients with photo-damaged skin on the face.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 PEP005 (ingenol mebutate) Gel Up to three days of treatment
- Primary Outcome Measures
Name Time Method To evaluate the safety of PEP005 Gel, 0.015% when administered for up to three consecutive days to photo-damaged skin on the face. Day 43
- Secondary Outcome Measures
Name Time Method To determine the efficacy of PEP005 Gel, 0.015% when administered for up to three consecutive days in patients with photo-damaged skin on the face. Day 43
Trial Locations
- Locations (2)
The Skin Centre
🇦🇺Benowa, Queensland, Australia
Specialist Connect
🇦🇺Woolloongabba, Queensland, Australia